Seeking Alpha

Arena Pharmaceuticals, Inc. (ARNA)

  • Tue, Mar. 24, 5:35 PM
    • Top gainers, as of 5:15 p.m.: KFX +45.3%. LXK +10.3%. ARNA +3.9%. RPTP +3.7%. CLDN +2.7%.
    • Top losers, as of 5:15 p.m.: CBK -7.2%. ENLK -5.7%. ENOC -4.6%. NSM -4.6%. TGS -3.9%.
    | Comment!
  • Tue, Mar. 3, 1:03 PM
    • Orexigen Therapeutics (OREX +53%) short sellers are licking their wounds today. Shares are up on a whopping 22x surge in volume in response to the news that patients taking its obesity med Contrave (naltrexone HCl/bupropion HCl) may reduce their risk of having a heart attack by almost 50%.
    • The data behind the news comes from an interim analysis of the 9,000-patient LIGHT study which is being conducted to determine the heart-safety profile of the obesity med. The analysis showed patients receiving Contrave experienced 35 major adverse cardiac events (MACE) compared to 59 for those taking placebo. The benefit was statistically significant. A MACE is a heart attack, stroke or heart-related death.
    • The company will conduct a second interim analysis of the data at 50% of events, which should happen in the next several weeks. Orexigen is also required to run a second heart-safety study as a condition of its clearance by the FDA in September 2014.
    • Contrave is sold in the U.S. by Takeda Pharmaceutical Co. (OTCPK:TKPHF) (OTCPK:TKPYY).
    • According to Yahoo Finance, almost 42% of Orexigen's float (more than 38M shares) was sold short as of February 13.
    • Related tickers: (VVUS +4.3%)(ARNA -5.5%)
  • Wed, Jan. 21, 9:14 AM
    | Comment!
  • Tue, Jan. 20, 5:38 PM
  • Tue, Jan. 20, 9:16 AM
    | Comment!
  • Wed, Jan. 7, 12:45 PM
    | 1 Comment
  • Wed, Jan. 7, 10:41 AM
    • Arena Pharmaceuticals (ARNA +33.4%) jumps on higher volume in early trading in response to its report of a dose-dependent effect on lymphocyte count lowering for APD334 in a Phase 1b trial.
    • Mean decreases in lymphocyte count in blood from baseline were as high as 69%. Counts recovered from baseline, on average, within one week of cessation of dosing. Lymphocyte lowering has been shown to correlate with clinical efficacy in Phase 2 and 3 trials of other S1P1 modulators in multiple sclerosis, psoriasis and ulcerative colitis.
    • APD334 is an oral drug that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. The company plans to proceed to Phase 2 development.
    • Related tickers: (OTCPK:ALIOF) (OTC:ALIOY) (NYSE:GSK) (OTCQX:RHHBY)
    | Comment!
  • Wed, Jan. 7, 9:20 AM
    | Comment!
  • Oct. 31, 2014, 5:39 PM
    | Comment!
  • Oct. 7, 2014, 5:40 PM
  • Jul. 21, 2014, 5:38 PM
  • Jul. 7, 2014, 12:24 PM
    • The legitimacy of any rosy pronouncements about Belviq's prospects by Arena Pharmaceuticals (ARNA -8.4%) CEO Jack Lief has been tarnished a bit with the disclosure of his disposal of a large portion of his holdings of ARNA stock. Mr. Lief felt compelled to unload almost 40% of his stake. Such a large transaction undermines the credibility of "asset diversification" and can only be construed as bearish behavior by the most significant company insider.
    • The ramp-up of Belviq sales has been underwhelming to most observers. Last quarter's sales were a modest $2.9M compared to Q2 2013's debut of $1.3M.
    • ARNA's stock is down 60% from its late June 2012 peak of $13.50. 208 mutual funds have positions, down from 210 a year earlier.
    • Consensus views remain bullish, however. Revenue estimates for Q2 and Q3 are $9.8M and $12.1M, respectively. Estimates for 2014 and 2015 are $43.8M and $85.7M, respectively.
    • The company should report Q2 results in mid-to-late August.
  • Jun. 20, 2014, 10:43 AM
    • Shares of new IPO Zafgen (ZFGN +1.2%) currently exchange hands for 24% above yesterday's offering price of $16 giving it a market cap of $430M. The company's lead product is beloranib, in Phase 2 clinicals to evaluate its safety and efficacy as a treatment for obesity.
    • The company has yet to produce any revenue. The IPO increased its cash and cash equivalents stake to ~$126M. It has spent ~$6M/year over the past three years developing beloranib. Operations consumed $15M in cash last year.
    • Related tickers: (VVUS -0.2%) (ARNA -1.2%) (OREX -2.6%)
  • Jun. 11, 2014, 6:18 PM
    • During a CNBC Fast Money appearance, Arena (ARNA) CEO Jack Lief was tight-lipped about rumors Belviq partner Eisai (ESALY) is interested in acquiring his company.
    • Investors trying to read between the lines see reasons to be hopeful.
    • Lief also mentioned Belviq prescriptions are seeing week/week growth.
  • Jun. 6, 2014, 2:36 PM
    • Arena Pharmaceuticals (ARNA -2.4%) is a strong sell on multiple red flags, says SA contributor The Pump Stopper.
    • Among these is the company's failure to disclose an SEC investigation, heavy insider selling, Belviq sales roughly 80% below expectations, and a new formidable competitor OREX awaiting what could be imminent FDA approval of its own product.
    • Price target: $1.25, or about 80% below the current level.
  • Feb. 27, 2014, 5:19 PM
    • Arena (ARNA) expects 2014 upfront payments from existing collaborations are to total $9M, development/patent reimbursements from Eisai $7M, and Siegfried manufacturing services $1M.
    • 2014 spending guidance: R&D of $90M-$98M, G&A of $30M-$36M, capex of $9M-$10M. 2013 R&D and G&A spend amounted to $66.5M and $31.7M, respectively.
    • Belviq product revenue totaled $2.4M in Q4, and partner Eisai has "doubled the size of the sales force detailing BELVIQ to approximately 400 representatives."
    • Cash/equivalents amounted to $221.9M at the end of 2013.
    • Q4 results, PR
Visit Seeking Alpha's
ARNA vs. ETF Alternatives
Company Description
Arena Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.
Sector: Healthcare
Industry: Biotechnology
Country: United States